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Background: HLA-haploidentical hematopoietic stem cell transplantation (HSCT) is suitable for patients lacking
related or unrelated HLA-matched donors. Herein, we investigated whether plerixafor (MZ), as an adjunct to G-CSF,
facilitated the collection of mega-doses of hematopoietic stem cells (HSC) for TCR-αβ/CD19-depleted haploidentical
HSCT, and how this agent affects the cellular graft composition.
Methods: Ninety healthy donors were evaluated. Single-dose MZ was given to 30 ‘poor mobilizers’ (PM) failing to
attain ≥40 CD34+ HSCs/μL after 4 daily G-CSF doses and/or with predicted apheresis yields ≤12.0x106 CD34+
cells/kg recipient’s body weight.
Results: MZ significantly increased CD34+ counts in PM. Naïve/memory T and B cells, as well as natural killer (NK)
cells, myeloid/plasmacytoid dendritic cells (DCs), were unchanged compared with baseline. MZ did not further
promote the G-CSF-induced mobilization of CD16+ monocytes and the down-regulation of IFN-γ production by T
cells. HSC grafts harvested after G-CSF + MZ were enriched in myeloid and plasmacytoid DCs, but contained low
numbers of pro-inflammatory 6-sulfo-LacNAc+ (Slan)-DCs. Finally, children transplanted with G-CSF + MZ-mobilized
grafts received greater numbers of monocytes, myeloid and plasmacytoid DCs, but lower numbers of NK cells,
NK-like T cells and Slan-DCs.
Conclusions: MZ facilitates the collection of mega-doses of CD34+ HSCs for haploidentical HSCT, while affecting
graft composition.Background
HLA-haploidentical hematopoietic stem cell transplan-
tation (HSCT) is an effective therapeutic option for
patients with high-risk leukemia, and without human
leukocyte antigen (HLA)-matched donors [1]. Historic-
ally, clinical success, i.e., full donor-type engraftment in
95% of patients with acute leukemia and negligible in-
cidence of acute and chronic graft-versus-host disease* Correspondence: sergio.rutella@gmail.com
1Department of Pediatric Hematology/Oncology and Transfusion Medicine,
IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
5Current address: Division of Translational Medicine, Research Branch, Sidra
Medical & Research Centre, Doha, Qatar
Full list of author information is available at the end of the article
© 2014 Rutella et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.(GVHD), has been achieved with T-cell depleted (TCD)
grafts containing a mega-dose of positively selected
CD34+ cells, without the use of any post-transplant
immunosuppression [2].
Granulocyte colony-stimulating factor (G-CSF) is widely
employed as mobilizing agent in healthy donors and cancer
patients. However, G-CSF-based regimens are associated
with a 5-30% failure rate [3]. The bicyclam AMD3100, also
known as plerixafor, was approved in 2008 for use in
combination with G-CSF to mobilize hematopoietic stem
cells (HSC) for autologous HSCT [4]. Plerixafor (Mozobil®,
MZ) specifically and reversibly blocks the binding of
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mokine and key regulator of HSC homing and reten-
tion in the bone marrow (BM). We previously showed
that G-CSF-mobilized peripheral blood CD34+ cells re-
tain surface CXCR4 [5], implying that BM microenviron-
ment might easily accommodate immigrating progenitor
cells that express high levels of CXCR4 following G-CSF
mobilization or stress conditions. MZ synergizes with
G-CSF through its different mechanism of action, as sug-
gested by randomized phase III studies, where plerixafor
and G-CSF were shown to be superior to G-CSF alone for
CD34+ HSC mobilization and collection [6,7].
Dendritic cells (DCs) are professional antigen-present-
ing cells triggering primary adaptive immune responses
through the activation of naïve CD4+ and CD8+ T cells
[8]. Initially, human DCs were categorized into type 1
(DC1) and type 2 DCs (DC2), which are functionally dis-
tinguished by pattern of cytokine production and T-cell
driving capacity. Recently, 3 cell types assigned to the
DC lineage have been characterized in human blood, i.e.,
type 1 myeloid DCs (MDC1), type 2 myeloid DCs
(MDC2) and plasmacytoid DCs [9-11]. Blood CD1c+
MDC1 efficiently cross-present soluble antigens and
prime cytotoxic T cells [12]. Human BDCA-3+ MDC2
share some characteristics with murine CD8α+ DCs,
such as production of high amounts of IL-12p70 and
interferon (IFN)-λ [10,11]. By contrast, human plasma-
cytoid DCs secrete IFN-α and activate natural killer
(NK) cells, macrophages and myeloid DCs to mount im-
mune responses against microbial products.
There is growing evidence that the biological activities
of G-CSF are not limited only to the myeloid lineage,
but extend to other cell types mediating, amongst the
others, inflammation, immunity and angiogenesis [13,14].
Initial studies in mice supported a role for G-CSF in im-
mune skewing towards T helper type 2 (Th2) cytokine
production [15]. In humans, G-CSF increases IL-4 release
and decreases IFN-γ secretion [16], and promotes the
differentiation of transforming growth factor-β1/IL-10-
producing type 1 regulatory T cells (Treg), which are
endowed with the ability to suppress T-cell proliferation
in a cytokine-dependent manner [17,18]. Finally, G-CSF
indirectly modulates DC function, by inducing hepa-
tocyte growth factor, IL-10 and IFN-α, and mobilizes
DC2 [19-21].
Currently, the use of MZ in healthy donors is off-
label, with anecdotal reports describing its ‘just-in-time’
application either as single agent or after mobilization
failure with G-CSF [22-24]. The few available data on
immunological effects of MZ are mostly limited to
cancer patients and show that CD8+ T-cell release of
IFN-γ and TNF-α may be higher in autologous grafts
collected after G-CSF and MZ, compared with G-CSF
alone [25].We recently developed a novel graft manipulation
strategy aimed at extensively removing T-cell receptor
(TCR)-αβ+ T cells and CD19+ B cells from haploidentical
HSCs, prior to their infusion into children with non-
malignant disorders [26]. TCR-αβ and B-cell depletion is
intended to prevent GVHD and post-transplantation lym-
phoproliferative disorders, respectively. The present study
was designed and conducted to investigate whether and to
what extent the administration of MZ, an ‘immediate sal-
vage’ strategy in donors with suboptimal CD34-cell counts
after standard-dose G-CSF, affects the cellular compos-
ition of the graft in the setting of TCR-αβ/CD19-depleted
haploidentical HSCT for children with hematological
disorders.Methods
Donor eligibility and treatment plan
Ninety healthy HLA-haploidentical parents of children
with hematological disorders were enrolled in the present
study. Our treatment algorithm is detailed in Figure 1.
Donors received MZ on a compassionate basis, outside
the approved label of the drug, after providing written in-
formed consent. The study was reviewed and approved by
the Institutional Ethics Committee (protocol #938-LB).
We opted for an ‘immediate salvage’ strategy administer-
ing 0.24 mg/kg MZ to donors failing to achieve the prede-
fined cutoff of ≥40 CD34+ HSCs/μL of blood after 4 daily
split-doses of 12 μg/kg G-CSF (Figure 1A) and/or donors
with suboptimal predicted apheresis yields on the ex-
pected day of HSC collection (≤12x106 CD34+ HSCs/kg of
recipient’s body weight; Figure 1B) [27]. MZ was adminis-
tered at 12:00 PM (day +4) and leukapheresis was per-
formed on day +5, following the morning dose of G-CSF
(i.e., 9 hours after MZ injection). Peripheral blood was col-
lected prior to G-CSF (day 0) and at peak CD34+-cell
counts (days +4 and +5). Normal BM samples were col-
lected from 10 consented donors performing BM dona-
tion under general anesthesia for matched-sibling HSCT.Antibodies and reagents
FITC-conjugated anti-IFN-γ, PE-conjugated anti-IL-17A,
PerCP-Cy5.5-conjugated anti-CD4 and APC-conjugated
anti-IL-4 monoclonal antibodies (mAbs; Human Th1/
Th2/Th17 Phenotyping Kit), Lineage Cocktail-1 (a mixture
of FITC-conjugated mAbs directed against CD3, CD14,
CD16, CD19, CD20 and CD56), BD™ Stem Cell Enumer-
ation Kit™, mAbs directed against human CD14, CD16,
CD45RO, CD62L, CD19, IgD, CD27 and CD184 (12G5
clone), Cytofix/Cytoperm™ solution and Golgi Plug Pro-
tein Transport Inhibitor™ were purchased from BD Biosci-
ences (Mountain View, CA). 6-sulfo-LacNAc+ (Slan)-DCs
were identified using a PE-conjugated anti-M-DC8
mAb (DD-1 clone; Miltenyi Biotec, Bologna, Italy).
Figure 1 CD34+ HSC mobilization algorithm. G-CSF was given subcutaneously at 12 μg/kg of body weight (divided into 2 doses, 12 hours
apart) for 4 consecutive days (D). On day +4, circulating HSCs were enumerated by flow cytometry, as detailed in Materials and Methods. Panels
A and B: If donors had ≤40 CD34+ cells/μL of blood on day +4 (and/or a predicted apheresis yield ≤12x106 CD34+ HSCs/kg of recipient’s body
weight) [27], a single dose of plerixafor (MZ) was administered subcutaneously (0.24 mg/kg of body weight), followed by HSC collection on day +5. If
donors had >40 CD34+ cells/μL of blood on day +4 (and/or a predicted apheresis yield >12x106 CD34+ HSCs/kg of recipient’s body weight),
mobilization was continued with G-CSF alone and HSCs were collected on day +5 (panel C).
Rutella et al. Journal of Translational Medicine 2014, 12:240 Page 3 of 14
http://www.translational-medicine.com/content/12/1/240Fluorochrome-conjugated mAbs directed against BDCA-1
(CD1c; AD5-8E7 clone; type 1 myeloid DCs or MDC1),
BDCA-2 (CD303; AC144 clone; plasmacytoid DCs),
BDCA-3 (CD141 or thrombomodulin; AD5-14H12 clone;
type 2 myeloid DCs or MDC2) and BDCA-4/neuropilin-1
(CD304; AD5-17 F6 clone; plasmacytoid DCs) were from
Miltenyi Biotec. Phorbol myristate acetate (PMA) and
ionomycin were purchased from Sigma-Aldrich (Milan,
Italy). The mAb panel and mAb combinations used for
graft characterization are detailed in Table 1.Table 1 Antibody panel used for graft characterization
FITC PE Per-CP APC Events analyzed (#)
CD20 - CD45 CD3 500,000
TCR-γδ TCR-αβ CD45 CD3 500,000
CD45 CD34 7-AAD - >100 CD34+ events
CD14 Slan-DC - CD16 50,000
CD3 CD16+CD56 CD45 CD19 50,000
CD8 CD4 CD45 CD3 50,000
Lineage 1 BDCA-4 - BDCA-2 50,000
Lineage 1 BDCA-3 - BDCA-1 50,000
FITC = fluorescein isothiocyanate; PE = phycoerythrin; Per-CP = Peridinin-
Chlorophyll-Protein; APC = allophycocyanin; TCR = T-cell receptor; 7-AAD =
7-amino-actinomycin-D; BDCA = blood dendritic cell antigen.Enumeration of CD34+ cells
CD34+ HSCs in donor PB, leukapheresis products and
manipulated grafts were counted using the ISHAGE
protocol [28].
TCR-αβ/CD19 immunomagnetic depletion
Leukapheresis collections containing <60.0x109 nucle-
ated cells were washed by centrifugation at 300 g for 15
minutes with PBS-EDTA-0.5% human serum albumin
(Clini-MACS® washing buffer; Miltenyi Biotec) and were
treated with γ-globulins to minimize the non-specific
antibody binding to Fc receptors, before the addition of
the biotin-conjugated, anti-TCR-αβ antibody. Cells were
then incubated with magnetic beads conjugated to anti-
biotin and to anti-CD19 antibodies, were re-suspended
at <300.0x106/mL and were applied to the fully auto-
mated Clini-MACS® device [29].
Enumeration of B-cell and T-cell subsets
The following B-cell subsets were monitored in HSC do-
nors: naïve B cells (CD19+CD27−IgD+), switched mem-
ory B cells (CD19+CD27+IgD−), non-switched memory B
cells (CD19+CD27+IgD+) and double-negative memory B
cells (CD19+CD27−IgD−). [30] Based on CD45RO and
CD62L expression, T cells were allotted to either of the
following subpopulations: naïve T cells (TN; CD45RO
−
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+
CD62L−), central memory T cells (TCM; CD45RO
+
CD62L+) and terminally differentiated effector T cells
(TEFF; CD45RO
−CD62L−) [31].
Enumeration of NK cells
Three NK-cell subsets were identified and counted.
Based on their reciprocal expression of CD16 and
CD56, CD3− cells within the lymphoid gate were subdi-
vided into fully mature NK cells (CD56+CD16+), tissue-
resident NK cells (CD56+CD16−) and immature NK
cells (CD56−CD16+) [32].
Enumeration of monocyte and DC subsets
Three monocyte subsets were analyzed based on CD14
and CD16 expression: classical (CD14++CD16−), inter-
mediate (CD14++CD16+) and non-classical monocytes
(CD14+CD16++) [9]. Intermediate and non-classical mo-
nocytes were collectively referred to as CD16+ mono-
cytes. To monitor DC mobilization, cells were stained
with the ‘Lineage Cocktail-1’ and with mAbs directed
against CD1c, CD303, CD141, or CD304 [33]. After gat-
ing on Lineage− events, DCs were enumerated and their
frequency was expressed as a percentage of total leuko-
cytes [9,33]. 6-sulfo-LacNAc+ (Slan)-DCs were counted
with the anti-M-DC8 antibody recognizing an O-linked
carbohydrate modification of P-selectin glycoprotein
ligand-1 [34].
Intracellular cytokine staining
Cytokine production at the single-cell level was assessed
with mAbs directed against IFN-γ, IL-17 and IL-4. CD4+
cells were activated for 4–6 hours with 50 ng/mL PMA
and 1 μg/mL ionomycin, in the presence of inhibitors
of protein transport. Following fixation and permea-
bilization, cells were labeled with cytokine-specific mAbs
for 30 minutes at 4°C and then analyzed by flow
cytometry.
Immunofluorescence analysis
After staining for surface antigens with mAbs at 4°C for
30 minutes, cells were incubated with 0.9% ammonium
chloride for 5 minutes to lyse residual red blood cells.
Cells were then extensively washed with PBS – 1% BSA
and were run on a FACS Canto II® flow cytometer (BD
Biosciences) with standard equipment. A minimum of
50,000 events was collected and acquired in list mode
using the FACS Diva® software package (BD Biosciences).
Statistical methods
The approximation of data distribution to normality was
tested preliminarily using statistics for kurtosis and sym-
metry. Data were presented as median and range, and
comparisons were performed with the Mann–WhitneyU test for paired or unpaired data, or with the Kruskal-
Wallis test with Bonferroni’s correction for multiple
comparisons, as appropriate. P values ≤ 0.05 denoted
statistical significance.
Results
MZ in adjunct to G-CSF potently mobilizes CD34+ HSCs in
healthy donors
We initially enumerated circulating CD34+ cells in healthy
donors receiving G-CSF for 4 consecutive days. Overall,
61 out of 90 donors (68%) failed to achieve the predefined
threshold of 40 CD34+ HSCs/μL of blood and were oper-
ationally defined as ‘poor mobilizers’ (PM; Figure 1C and
Figure 2). However, 31 out of these 61 donors (51%) were
re-assigned to the ‘good mobilizer’ (GM) group, since the
prediction algorithm favored an apheresis yield >12x106
CD34+ HSCs/kg of recipient’s body weight (Figure 1C). By
contrast, 29 out of the 90 donors (32%) had post-
mobilization CD34-cell counts greater than the cutoff
value of 40 CD34+ HSCs/μL on day +4, and were classi-
fied as ‘good mobilizers’ (GM). Collectively, 60 donors fell
into the GM category, whereas the remaining 30 PMs
(33% of the whole donor cohort) received single-dose MZ.
In GMs and PMs, the frequency (Figure 2A) and num-
ber (Figure 2B) of circulating CD34+ HSCs were 0.10%
(range 0.02-0.25) and 0.05% (0.01-0.09; p < 0.0001), and
36.5 cells/μL (5–110) and 16.0 cells/μL (2–36; p <
0.0001), respectively, on day +4 of G-CSF administra-
tion. Figure 2B also illustrates that CD34+-cell counts
further increased on day +5 in GMs given G-CSF alone,
when compared with those recorded on day +4. PMs
consistently achieved >40 CD34+ cells/μL of blood after
single-dose MZ, and their CD34+ counts on day +5 were
even higher when compared with those measured in
GMs given G-CSF alone [135.0 cells/μL (40–277) vs.
99.0 cells/μL (29–232); p = 0.0089]. Interestingly, PMs
given single-dose MZ had higher day-5 monocyte and
lymphocyte counts compared with GMs receiving G-CSF
alone (Figure 2C-D). The role of MZ in mobilizing mono-
cytes and lymphocytes was further reinforced by the ob-
servation that PMs and GMs had similar monocyte and
lymphocyte counts on day +4, before receiving single-dose
MZ (Figure 2C-D).
As expected, larger numbers of CD34+ HSCs were col-
lected, with one single apheresis session, after mobilization
with G-CSF +MZ compared with G-CSF alone (Table 2).
However, children whose HSC donors were given MZ
had a significantly greater body weight compared with
children transplanted with G-CSF-mobilized HSC prod-
ucts [45.0 kg (18–74) vs. 20.5 kg (4–66); p < 0.0001].
Effects of MZ on circulating immune cells
It is presently unknown whether single-dose MZ affects
T-cell and B-cell phenotype in G-CSF-treated healthy
Figure 2 CD34+ HSC, monocyte and lymphocyte mobilization with G-CSF and plerixafor (MZ). Relative frequency (panel A) and absolute
number (panel B) of CD34+ HSC, as well as absolute monocyte (panel C) and lymphocyte counts (panel D), are shown in ‘good mobilizers’
(GMs) and ‘poor mobilizers’ (PMs) on day +4 (left graph) and day +5 (right graph). The green bar denotes the median value. Comparisons were
performed with the Mann–Whitney U test for paired data. The dotted red line in panel B refers to the predefined cutoff of 40 CD34+ HSCs/μL of
blood used on day +4 to discriminate the PMs from the GMs. The dotted red line in panels C and D indicates the upper normal limit (UNL) of
monocyte and lymphocyte count. WBC = white blood cells.
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samples from donors receiving either G-CSF alone or
G-CSF and MZ. No statistically significant differences
in the relative proportion of TCR-αβ and TCR-γδ-
expressing CD3+ T cells were detected, when comparing
baseline [94.0% (88.8-98.8) and 5.4% (1.0-9.1), respectively]
and post-mobilization samples [95.6% (86.5-99.3) and 4.0%
(0.6-12.7), respectively], irrespective of the mobilization
protocol (Additional file 1). Moreover, the frequency of TN,
TCM, TEM and terminally differentiated effectors was com-
parable in baseline and post-mobilization samples. Specif-
ically, TN cells accounted for 29.7% (2.4-62.2) and 30.9%
(1.0-58.7), and for 32.2% (2.4-56.4) and 26.6% (2.0-53.4)
of the CD4+ and CD8+ T cells before and after treat-
ment with G-CSF (Additional file 1), indicating thatTable 2 Number of CD34+ HSCs harvested and infused
according to the mobilization regimen
CD34+ HSC yield
G-CSF alone G-CSF + MZ P value
Harvested CD34+ HSCs
Median 462.6x106 655.9x106 0.0008
Range 93.2-1,216 176.5-1,284
Infused CD34+ HSCs
Median 19.83x106/kg 16.83x106/kg 0.0044
Range 7.5-79.0 5.8-29.21
MZ = plerixafor (Mozobil®); HSC = hematopoietic stem cells. Comparisons
between groups were performed with the Mann-Whitney U test for
unpaired determinations.G-CSF administration had no apparent effect on the
re-circulation of individual T-cell subsets. We also quanti-
tated B-cell subpopulations in mobilized donors. Again,
no appreciable differences were detected in the frequency
of naïve B cells, double-negative B cells, switched memory
B cells and non-switched memory B cells (Additional
file 2). Furthermore, the addition of MZ to the G-CSF-
based mobilization regimen exerted no measurable effect
on the relative frequency of T-cell and B-cell subsets (data
not shown). Previous studies showed that G-CSF skews T-
cell function towards a regulatory profile, both in mice
and in humans [15,17]. We thus measured the frequency
of CD4+ T cells expressing intracellular IFN-γ, IL-17 and
IL-4 at baseline and after mobilization with G-CSF.
Figure 3A-B illustrates that the frequency of IFN-γ-
expressing CD4+ T cells was significantly lower in mobi-
lized PB samples compared with baseline. By contrast,
IL-4- and IL-17-producing T cells were unchanged. Intri-
guingly, no differences were found in the frequency of
IFN-γ-expressing CD8+ T cells (Figure 3C). When data
were dichotomized based on the mobilization regimen
used, no statistically significant differences were detected
in the frequency of CD4+ and CD8+ T cells expressing
intracellular IFN-γ (Figure 3D).
As shown in Figure 4A-B, the overall frequency of PB
NK cells was significantly lower after HSC mobilization
compared with baseline. This reduction was mainly ac-
counted for by the subgroup of PMs who were given MZ
(Figure 4B). Notably, both fully mature CD56+CD16+ NK
cells and tissue-resident CD56+CD16− NK cells were
Figure 3 T-cell cytokine secretion profile after mobilization with G-CSF and plerixafor (MZ). PBMCs from 18 randomly selected donors
given G-CSF alone (G; n = 11) or G-CSF and plerixafor (MZ; n = 7) were stimulated with polyclonal activators in vitro and then fixed, permeabilized
and stained with anti-IFN-γ/IL-17/IL-4 mAbs. Panel A: Percentage of cytokine-expressing CD4+ T cells at baseline and after mobilization. Bars
denote the median value. Comparisons were performed with the Mann–Whitney U test for paired determinations. Panel B: A representative
experiment for the enumeration of Th1, Th17 and Th2 CD4+ T cells is shown. The percentage of cells staining positively for each cytokine is
indicated. Markers were set according to the proper isotypic control (not shown). Panel C: Percentage of IFN-γ-expressing CD8+ T cells at baseline
and after mobilization. Bars denote the median value. Panel D: Percentage of IFN-γ-expressing CD4+ and CD8+ T cells in healthy donors assigned
to the GM (G-CSF alone) and to the PM group (G-CSF +MZ). Bars denote the median value. Differences were not statistically significant.
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immature CD56−CD16+ NK cells were not affected by the
HSC mobilization regimen (Figure 4C). Mirroring the
above data on NK cells, the frequency of NK-like CD56+
T cells was also reduced after G-CSF mobilization, espe-
cially in PMs given single-dose MZ (Figure 4D). Collect-
ively, these experiments suggest that NK cells and NK-like
T cells may be less represented in healthy donors given G-
CSF-based mobilization and that this phenomenon is ac-
centuated by the co-administration of MZ.
We then aimed at enumerating monocyte and DC
subsets in mobilized donors. Classical, intermediate and
non-conventional monocytes were labeled and quantitated
as shown in Figure 4E. Although the frequency of con-
ventional CD14+CD16− monocytes was not significantly
different in baseline compared with post-mobilization
samples, the proportion of CD16+ monocytes increased
after G-CSF administration, both in the GM and in the
PM group (Figure 4F-G). Slan-DCs (Figure 5A) were not
appreciably mobilized into PB by treatment with G-CSF,
either alone or combined with MZ (data not shown). Be-
cause G-CSF induces CXCR4 cleavage and disrupts the
CXCR4/SDF-1α interaction during HSC mobilization,[35] we reasoned that a differential regulation of CXCR4
expression on the surface of Slan-DCs could account for
low-level Slan-DC mobilization after combined treatment
with G-CSF and MZ. As depicted in Figure 5B, CXCR4
expression significantly decreased on monocytes from do-
nors given G-CSF, after labeling with CD184-12G5 anti-
bodies. Comparable reductions were measured on other
leukocyte subsets, such as lymphocytes and neutrophils
(data not shown). By contrast, CXCR4 was not apparently
down-regulated on circulating Slan-DCs, irrespective of
the mobilization regimen (Figure 5C).
Finally, no changes were recorded in the frequency of
MDC1, MDC2 or plasmacytoid CD303+ or CD304+ DCs
when comparing baseline and post-mobilization sam-
ples, irrespective of the mobilization regimen (Additional
file 3) and in keeping with previous reports showing no
changes in the frequency of BDCA-2+ DCs in donors
given G-CSF [36]. Collectively, these experiments sug-
gest that single-dose MZ exerts no major effects on
circulating B-cell and T-cell subsets and on monocyte/
DC subpopulations, although it may reduce the fre-
quency of blood NK cells and NK-like T cells, when
compared with G-CSF alone.
Figure 4 Mobilization of NK cells, NK-like T cells and monocytes with G-CSF and plerixafor (MZ). Panel A: Donor PBMCs were labeled with
mAbs directed against CD3, CD16 and CD56 to enumerate classical NK cells, NK-cell subsets and NK-like T cells. A representative experiment illus-
trating the gating strategy for the analysis of NK cells and NK-like T cells is shown. After gating on CD3- events (P2), dot plots were used to
visualize the reciprocal expression of CD16 and CD56 on NK-cell subsets. Panel B: The percentage of NK cells within the lymphoid gate (lymphs)
is plotted. PB samples from 40 randomly selected donors were used for this analysis. GM = ‘good mobilizers’; PM = ‘poor mobilizers’; before = baseline
samples; after = samples collected after HSC mobilization. Bars indicate the median value. Comparisons were performed with the Mann Whitney U test
for paired determinations. Panel C: The percentage of each subset/total NK cells is plotted on y axes. Bars indicate the median value. Comparisons
were performed with the Mann Whitney U test for paired determinations. Before = baseline samples; after = samples collected after HSC mobilization.
Panel D: Percentage of NK-like T cells within the lymphoid gate. Bars indicate the median value. Comparisons were performed with the Mann Whitney
U test for paired determinations. Panel E: Strategy to enumerate monocyte subsets in donors’ PB. Cells with a CD14++CD16- phenotype were
considered to be conventional monocytes (Mo.); conversely, cells with a CD14+CD16+ (intermediate monocytes, Int.) or a CD14+CD16++ phenotype
(non-conventional monocytes, NC) were referred to as CD16+ monocytes [9,55]. No statistically significant differences emerged when comparing the
frequency of monocytes before and after G-CSF ± MZ (panel F). WBC = white blood cells. The frequency of CD14+CD16- and CD14+CD16+ monocytes
before and after HSC mobilization is depicted in panel G. Bars indicate median values. Comparisons were performed with the Mann-Whitney U test for
paired determinations.
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In 70 randomly selected HSC donors (43 GMs given
G-CSF only and 27 PMs receiving G-CSF plus MZ)
undergoing a standard large-volume (15-20 L) leuka-
pheresis, the graft was extensively characterized in terms
of immune effector cells with particular relevance to the
setting of haploidentical HSCT, such as NK cells, CD3+
CD56+ NK-like T cells, monocytes and DCs. [37-39] For
the purpose of comparison, we also enumerated im-
mune effectors in 10 BM samples from healthy HLA-
identical sibling donors. TCR-αβ/CD19-depleted grafts
obtained after either mobilization regimen were highly
enriched with NK cells compared with normal BM sam-
ples (Figure 5D). However, the frequency and absolute
numbers of NK cells were comparable in grafts collectedafter the administration of either G-CSF alone or G-CSF
and MZ (Figure 5D-E). Although grafts from donors
assigned to the GM group had a higher frequency of NK-
like CD56+ T cells compared with those from the PM
group (Figure 5F), the overall number of CD56+ NK-like T
cells harvested was similar (Figure 5G).
Both conventional and CD16+ monocytes were con-
tained at higher frequency in TCR-αβ/CD19-depleted
grafts, compared with normal BM samples (Figure 6A-B).
As shown in Figure 6C-D, both monocyte populations
were more abundant in G-CSF +MZ-mobilized grafts
compared with grafts collected after G-CSF alone. 6-sulfo-
LacNAc+ (Slan) DCs constitute 0.5-2% of all PBMCs, are
CD14lowCD16+ and are a highly phagocytic monocyte
subset inducing potent pro-inflammatory Th1 and Th17
Figure 5 Expression of CXCR4 (CD184) on Slan-DCs and numbers of NK cells and NK-like T cells in HSC grafts collected after
mobilization with G-CSF and plerixafor (MZ). Panel A shows the results of a representative experiment aimed at enumerating 6-sulfo-LacNAc+
(Slan)-DCs in donors’ PB. Slan-DCs were consistently CD16+ and expressed low-level CD14. Panels B and C: PB samples from PMs given G-CSF
and single-dose MZ were double-stained with anti-CD184 and anti-M-DC8 mAbs to quantitate CXCR4 expression on Slan-DCs. The Mean Fluorescence
Intensity (MFI) of CD184 expression on peripheral CD14+ monocytes is shown in a representative experiment out of 4 with similar results. The marker
was set according to the proper isotypic control. Panel C shows preserved levels of CD184 on Slan-DCs after HSC mobilization with G-CSF and MZ.
This is in contrast with the marked down-regulation of CD184 on monocytes that is depicted in panel B. One representative experiment out of 4 with
similar results is shown. Markers were set according to proper isotypic controls. Panels D-G: Frequency and absolute numbers of NK cells and NK-like T
cells in TCR-αβ/CD19-depleted haploidentical grafts. After the immunomagnetic removal of TCR-αβ+ T cells and CD19+ B cells, mononuclear cells
contained within the graft were extensively characterized using mAbs directed against CD3, CD16 and CD56 with the aim at identifying NK cells and
NK-like T cells. NK cells and NK-like T cells were also quantitated in aliquots of 10 normal BM samples collected under general anesthesia and intended
for HLA-identical sibling HSCT. Comparisons among data sets were performed with the Mann Whitney U test for unpaired determinations or with the
analysis of variance (ANOVA), as appropriate. HC = healthy control; WBC = white blood cells.
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quency of Slan-DCs was significantly lower in grafts
mobilized with G-CSF +MZ (0.85% of total leukocytes,
0.06-1.3) compared with G-CSF alone (1.4%, 0.5-4.15; p =
0.0045), although this did not translate into the collection
of lower numbers of Slan-DCs.
Finally, Figure 7 shows that both MDC2 and plasma-
cytoid DCs were significantly more represented in grafts
collected after mobilization with G-CSF and MZ. Thus,
the number of MDC1, MDC2 and plasmacytoid DCs
collected from donors given G-CSF and MZ was signifi-
cantly greater. Also, the frequency of DC subsets was
higher in TCR-αβ/CD19-depleted grafts compared with
normal BM samples (Figure 7). Table 3 summarizes the
absolute numbers of cells infused in children receiving
the TCR-αβ/CD19-depleted haploidentical grafts collec-
ted after G-CSF alone or G-CSF +MZ. Whereas the num-
ber of monocytes and DCs infused in the two patientgroups was similar, children given G-CSF-mobilized grafts
received significantly greater numbers of NK cells and
NK-like T cells, as well as pro-inflammatory Slan-DCs,
compared with children given HSCT from donors mobi-
lized with G-CSF +MZ (Table 3). These differences can
be accounted for by the significantly higher number of nu-
cleated cells collected from GMs treated with G-CSF
alone (Table 3). Also, the fact that children receiving hap-
loidentical HSCT from GMs had a lower body weight may
have translated into the infusion of higher numbers of NK
cells, NKT cells and Slan-DCs.
From a clinical standpoint, neither the HSC mobili-
zation regimen (G-CSF alone vs. G-CSF and MZ) nor
the number of monocytes and DCs infused correlated
with either the occurrence of acute GVHD or the reacti-
vation of viral infections (data not shown). By contrast,
patients who developed chronic GVHD had received
lower numbers of conventional CD14+CD16− monocytes
Figure 6 Numbers of monocytes and Slan-DCs in HSC grafts collected after mobilization with G-CSF and plerixafor (MZ). After the
immunomagnetic removal of TCR-αβ+ T cells and CD19+ B cells, mononuclear cells contained within the graft were extensively characterized
using mAb directed against surface antigens known to be expressed on monocytes and on pro-inflammatory Slan-DCs. Monocytes and Slan-DCs
were also quantitated in normal BM samples from matched-sibling donors. The frequency and absolute numbers of CD14+CD16− and CD14+CD16+
monocytes in TCR-αβ/CD19-depleted haploidentical grafts are depicted in panels A-D. The frequency and absolute number of Slan-DCs are shown in
panels E-F. The green bars indicate median values. GM = ‘good mobilizers’; PM = ‘poor mobilizers’; HC = healthy control. Comparisons among data sets
were performed with the Mann Whitney U test for unpaired determinations or with the analysis of variance (ANOVA), as appropriate.
Figure 7 Numbers of myeloid and plasmacytoid DCs in HSC grafts collected after mobilization with G-CSF and plerixafor (MZ). After the
immunomagnetic removal of TCR-αβ+ T cells and CD19+ B cells, mononuclear cells contained within the graft were extensively characterized
using mAbs directed against surface antigens selectively expressed on DC subpopulations [33]. DC subsets were also quantitated in aliquots of 10
normal BM samples from matched-sibling donors. Panels A and B depict the frequency and number of MDC1 and plasmacytoid CD303+ DCs,
respectively, whereas panels C and D show the frequency and number of MDC2 and CD304+ plasmacytoid DCs, respectively. Comparisons among
data sets were performed with the Mann Whitney U test for unpaired determinations or with the analysis of variance (ANOVA), as appropriate.
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Table 3 Number of nucleated cells, NK cells, monocytes
and DCs infused (per kg of recipient’s body weight)
according to the mobilization regimen
G-CSF alone G-CSF + MZ P value
Total NC
Median 1.17x109/kg 0.71x109/kg 0.0002
Range 0.33-2.99 0.28-1.6
NK cells
Median 31.3x106/kg 16.8x106/kg 0.0016
Range 1.8-176.8 2.8-55.9
NK-like T cells
Median 3.64x106/kg 1.56x106/kg 0.0016
Range 0.4-34.8 0.2-6.64
CD16- monocytes
Median 312.2x106/kg 226.8x106/kg 0.34
Range 15.9-729.8 28.5-667.0
CD16+ monocytes
Median 74.9x106/kg 63.6x106/kg 0.46
Range 1.5-231.7 8.3-169.6
Slan-DCs
Median 1.40x106/kg 0.85x106/kg 0.0008
Range 0.5-4.14 0.06-1.27
CD1c+ MDC1
Median 0.84x106/kg 0.88x106/kg 0.88
Range 0.1-13.1 0.04-9.66
CD303+ pDCs
Median 4.12x106/kg 4.73x106/kg 0.82
Range 0.72-13.66 0.61-22.9
CD141+ MDC2
Median 3.74x106/kg 4.15x106/kg 0.55
Range 0.36-14.5 0.33-22.4
CD304+ pDCs
Median 3.8x106/kg 3.1x106/kg 0.78
Range 0.2-13.0 0.2-14.7
NC = nucleated cells; MZ = plerixafor (Mozobil®); MDC1 = type 1 myeloid DCs;
MDC2 = type 2 myeloid DCs. Comparisons between groups were performed
with the Mann-Whitney U test for unpaired determinations.
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chronic GVHD (11.45×106/kg, 0.6-144.2; p = 0.016].
Discussion
Herein, we show that the addition of ‘immediate salvage’
MZ to a standard, G-CSF-based mobilization regimen
augments HSC yield in HLA-haploidentical donors
showing less-than-optimal CD34-cell mobilization, and
that MZ administration affects the graft cell compos-
ition. Thirty-two percent of our donors were operation-
ally defined as PMs and were given MZ to increase HSCmobilization. More than 95% of the donors collected the
required mega-dose of HSCs with a single apheresis
session.
Currently, anecdotal reports describe the ‘just-in-time’
application of MZ to healthy donors, either as single
agent or after mobilization failure with G-CSF [22-24].
In our donor cohort, single-dose MZ given on day +5
increased the count of CD34+ HSCs by 8.2-fold (range
1.4-29.2), compared with that measured after 4 days of
G-CSF treatment. This is remarkably similar to the 8-
fold increase of CD34+ HSCs reported in donors given
MZ only [23].
The few available data on immunological effects of
MZ are mostly limited to cancer patients and show that
CD8+ T-cell release of IFN-γ and TNF-α may be higher
in autologous grafts collected after G-CSF and MZ,
compared with G-CSF alone [25]. We previously showed
that G-CSF polarizes human T-cell and DC function
towards a tolerogenic profile, implying that G-CSF-
mobilized cell therapy products may be intrinsically less
capable of inducing uncontrollable GVHD [17,19,41].
This is reinforced by intriguing observations in major his-
tocompatibility complex (MHC)-matched HSCT, where
mice given G-CSF-mobilized splenocytes experienced
lower rates of skin GVHD compared with recipients
of MZ-mobilized splenocytes [42]. In our healthy do-
nors treated with G-CSF, the down-regulation of CD4+
T-cell production of IFN-γ was not potentiated by single-
dose MZ. Furthermore, IL-17 and IL-4 release by CD4+ T
cells were not affected by G-CSF and/or MZ administra-
tion. These observations are in line with pre-clinical data
showing that MZ alone, in contrast to G-CSF, is unable to
alter the phenotype and cytokine polarization of T cells, as
well as T-cell’s ability to induce acute GVHD [43]. It must
be emphasized that, in our study, neither G-CSF nor MZ
significantly impaired IFN-γ production by CD8+ T cells.
Notably, studies in mice suggest that G-CSF may separate
GVHD and graft-versus-leukemia (GVL) responses by
exerting suppressive effects on CD4+ T cells, that are im-
plicated in GVHD, while preserving the cytolytic pathways
of CD8+ T cells that are critical for effective GVL [44]. At
variance with a recent report on the immunological effects
of single-dose MZ in healthy donors [42], we were unable
to detect any difference in the frequency of naïve B cells
after MZ administration. Conceivably, any MZ effect on
the recirculation of B-cell subsets may have been ob-
scured by treatment with G-CSF during the 4 days pre-
ceding MZ administration. However, neither that study
[42] nor our own report identified any modification of
CD4 and CD8 T-cell frequencies that could be directly
attributable to MZ.
In our cohort of 90 donors, HSC mobilization with
G-CSF translated into lowered frequencies of both NK
cells and NK-like CD56+ T cells, a phenomenon that
Rutella et al. Journal of Translational Medicine 2014, 12:240 Page 11 of 14
http://www.translational-medicine.com/content/12/1/240was mainly accounted for by a reduction of fully ma-
ture CD56+CD16+ and tissue-resident CD56+CD16− NK
cells, with preserved frequencies of immature CD56−CD16+
NK cells. Interestingly, the frequency of both NK cells and
NK-like CD56+ T cells was reduced in the PM group re-
ceiving single-dose MZ. Although the number of NK cells
collected was not significantly different when comparing
donors given G-CSF alone with those receiving G-CSF in
combination with MZ, higher numbers of both NK cells
and NK-like CD56+ T cells were infused in children trans-
planted with G-CSF-mobilized HSC products. A potential
clinical implication of this finding pertains to the field
of graft engineering, insofar donor mobilization with
G-CSF alone might offer an advantage over the use of
G-CSF +MZ for patients with NK-susceptible hematolo-
gical malignancies [37].
As previously published, G-CSF-mobilized monocytes
are functionally defective [45]. In our study, treatment
with G-CSF and MZ potently mobilized donor mono-
cytes, especially the CD16+ subset of intermediate/non-
conventional monocytes. Although the frequency of both
conventional and CD16+ monocytes was higher in TCR-
αβ/CD19-depleted HSC grafts compared with normal BM
samples, the overall number of conventional and CD16+
monocytes infused in our haploidentical HSCT recipients
was not correlated with the mobilization regimen used in
the donor. It has been demonstrated that macrophages
generated from CD16+ monocytes manifest higher phago-
cytic activity compared with macrophages derived from
classical monocytes [46]. In addition, CD14dimCD16+
monocytes are endowed with a unique patrolling function,
as they detect virally infected and damaged cells and pro-
duce pro-inflammatory cytokines [47]. In light of these
findings, it is conceivable that CD16+ monocytes infused
with the TCR-αβ/CD19-depleted haploidentical grafts
may protect the recipient from infectious episodes, while
contributing to prevention of GVHD [48].
There is also evidence that G-CSF mobilizes IL-12/
TNF-α-producing, pro-inflammatory Slan-DCs [49]. Thus,
Slan-DCs may incite GVHD on the one side, while pre-
serving GVL reactivity on the other side. In our study,
the addition of MZ to G-CSF did not affect the mo-
bilization of Slan-DCs. In addition, the frequency of
Slan-DCs was lower in HSC grafts collected after the
combined treatment with G-CSF and MZ. Because G-CSF
administration is associated with in vivo cleavage of
the N-terminus of CXCR4 on BM-resident HSCs [35],
it is tempting to speculate that Slan-DCs, at variance
with CD34+ HSCs and monocytes [5,50], may not en-
tirely depend upon the CXCR4/SDF-1α axis for re-
circulation and homing into lymphoid organs and/or
tissues. Our contention is backed by experiments with
CD184-12G5 antibodies showing that CXCR4 levels are
preserved on the surface of Slan-DCs, but not otherleukocyte subsets, analyzed after the in vivo adminis-
tration of G-CSF, when compared to G-CSF plus MZ,
this likely favoring Slan-DC retention into tissues. The
CD184-12G5 mAbs recognize an epitope involving the
first and second extracellular domains of CXCR4, and
inhibit MZ binding to CXCR4. A different anti-CXCR4
mAb, termed 1D9, binds to the N terminus of CXCR4
and is not affected by MZ [51]. In a phase 1/2 study
of chemo-sensitization with MZ in relapsed or refrac-
tory acute myeloid leukemia, a decrease in CD184-
12G5 binding was observed from pre-treatment to 6
hours, followed by an increase from 6 to 24 hours, in-
dicating CXCR4 blockade by MZ in vivo [52]. By con-
trast, labeling with CD184-1D9 after MZ treatment
revealed an increased expression of CXCR4 between
pretreatment and 6 hours, that remained elevated at
24 hours.
Finally, the frequency of CD1c+ MDC1, CD141+ MDC2
and plasmacytoid DCs [33] was unchanged in PB of do-
nors treated with G-CSF, either alone or in combination
with MZ. This is in agreement with previous reports sho-
wing no changes in the frequency of BDCA-2+ DCs in
donors given G-CSF compared with baseline [36]. The
TCR-αβ/CD19-depleted haploidentical grafts collected
after the administration of G-CSF and MZ were highly
enriched with MDC1, MDC2 and plasmacytoid DCs,
when compared with normal BM samples. The role played
by DCs in the regulation of human GVHD and GVL
responses is the subject of intense investigation. Stud-
ies of BM transplantation have shown that high num-
bers of plasmacytoid DCs in the graft correlate with
decreased chronic GVHD, at the expense of an increased
incidence of leukemia relapse [53]. Conversely, the num-
ber of DCs in PB allografts may not predict DC reconsti-
tution kinetics after transplantation or clinical outcome
[54]. Importantly, low DC counts at time of engraftment
have been associated with worse survival, increased inci-
dence of relapse and higher incidence of grade II-IV acute
GVHD [54].
Thus far, we have transplanted 23 children with non-
malignant disorders using TCR-αβ/CD19-depleted HSC
grafts [26]. Primary graft failure occurred in 4 patients,
with 3 patients developing skin-only grade 1 to 2 acute
GVHD and no patient suffering from chronic GVHD.
The cumulative incidence of transplantation-related mor-
tality was 9.3%. With a median follow-up of 18 months,
21 of 23 children are alive and disease-free, the 2-year
probability of disease-free survival being 91.1% [26]. It
remains to be determined whether and to what extent
the DC content of our TCR-αβ/CD19-depleted HSC
grafts and, in particular, the remarkably high numbers
of MDC1, MDC2 and plasmacytoid DCs infused cor-
relate with infection control, GVHD and/or leukemia
recurrence.
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Collectively, our study shows that MZ is highly effective at
mobilizing mega-doses of CD34+ HSCs to be transplanted
into haploidentical recipients. Furthermore, our data shed
some light into the optimal clinical use of MZ, insofar dif-
ferences in graft cellular composition after mobilization
with G-CSF and MZ are expected to quantitatively and/or
qualitatively influence the immune processes that occur
after allogeneic HSCT.Additional files
Additional file 1: Phenotype of circulating T-cell subsets after
mobilization with G-CSF. PB samples from 21 randomly selected donors
were analyzed for the relative frequency of TCR-αβ/γδ T cells as well as
naïve/memory T-cell subsets. Panel A: Lymphoid cells were gated based
on their light scatter characteristics and on CD3 expression (P1), followed
by the analysis of reciprocal αβ and γδ-chain expression. Panel B: The
frequency of CD3+ T cells/total lymphoid cells, αβ+ T cells/total CD3+ T
cells and γδ+ T cells/total CD3+ T cells is shown before and after G-CSF
administration. Bars indicate the median value recorded in 21 independent
donor samples. Panels C-D: T-cell subsets were identified through labeling
with anti-CD62L and anti-CD45RO mAb, which allowed the discrimination
of naïve T cells (TN) from central-memory T cells (TCM), effector-memory T
cells (TEM) and terminally differentiated effectors. Bars indicate the median
value recorded in 21 independent donor samples. TCR = T-cell receptor.
Additional file 2: Phenotype of circulating B-cell subsets after
mobilization with G-CSF. PB from 21 randomly selected donors were
analyzed for the relative frequency of naïve/memory B-cell subsets.
Panel A: mAbs directed against CD19, CD27, IgM and IgD were used to
discriminate naïve B cells from memory B-cell subsets [30]. Panel B: The
frequency of B-cell subsets/total CD19+ B cells is shown before and after
G-CSF administration. N = naïve B cells (CD19+CD27−IgD+); S-M = switched
memory B cells (CD19+CD27+IgD−); NS-M = non-switched memory
B cells (CD19+CD27+IgD+); DN-M = double-negative memory B cells
(CD19+CD27−IgD−). Bars indicate the median value recorded in 21
independent donor samples.
Additional file 3: Circulating DC subsets after mobilization with
G-CSF and plerixafor (MZ). PB samples from 40 randomly selected
donors (24 GMs given G-CSF alone and 16 PMs receiving G-CSF + MZ)
were analyzed for the relative frequency of major DC subsets. MDC1,
MDC2 and plasmacytoid DCs were identified as detailed in Materials and
Methods. Bars denote the median value. Before = baseline samples;
after = samples collected after HSC mobilization.Competing interests
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